2-Amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) induced high levels of circulating interferon in mice when administered either parenterally or orally. Peak titers of interferon were found in the serum between 6 and 12 h after inoculation of the drug. Lower but significant levels of interferon were found in rat serum after administration of U-25, 166 by either the intraperitoneal or oral route, and good levels of circulating interferon were observed in cats after oral treatment. Repeated intraperitoneal doses (50 mg/kg) of U-25, 166 protected mice against intranasal encephalomyocarditis virus challenge. The minimal effective acute oral dose for antiviral activity was approximately 250 mg/kg. This was also the minimal dose that produced detectable levels of interferon. Maximum tolerated doses in mice were four to six times the minimal effective doses. A single oral treatment was protective in mice against challenge virus inoculated 24 h later. The compound protected mice from challenge with high levels of encephalomyocarditis virus, up to 20,000 mean lethal doses. Antiviral activity in mice was retained when certain minor substitutions were made in the U-25,166 structure.
Practical use of interferon in human viral disease may ultimately be achieved, either by administering exogenous interferon or by stimulating production of endogenous interferon. Several chemically defined, nonpolymeric, relatively low-molecular-weight compounds have been reported to stimulate interferon production in laboratory models (4, 5, 7, 8, 10) . These interferon inducers represent a diversity of chemical structures, and all differ structurally from an inducer discovered in our laboratory. This report describes the antiviral activity and interferon-stimulating properties of a substituted pyrimidine, 2-amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) (see Fig. 1 ).
MATERIALS AND METHODS Animals. (i) Mice. Mice were of random sex and weighed 16 ± 2 g. Upj:TUC(ICR)spf and Upj: TUC(CF-l)spf strains were provided by the Upjohn Animal Rearing and Procurement Unit. The CF-W mice were purchased from Carworth Laboratories (Kalamazoo, Mich.); S/W mice were from Camm Research (Wayne, N.J.); and the C57/Bl/6J mice, an inbred strain, were from Jackson Memorial Laboratories (Bar Harbor, Me.). All mouse studies were done with ICR mice unless otherwise indicated.
(ii) Rats (iii) Cats. Mixed-breed barn cats, weighing from 1.7 to 3.3 kg each, were obtained from area farmers.
Drug. U-25,166 was purchased from Aldrich Chemical Co. (Milwaukee, Wis.). The compound is only slightly soluble in water (approximately 0.3 mg/ml at 25 C); therefore, it was finely ground in a glass tissue grinder (Ace Glass, Inc., Vineland, N.J.) and suspended in sterile aqueous 1% carboxymethylcellulose (CMC) for treating animals.
Drug administration and blood collection. (i) Mice. Drug was administered by various routes by standard procedures. Groups of 15 mice were bled by decapitation, the pooled blood was stored overnight at 4 C, and the serum was collected.
(ii) Rats. Drug was administered by standard procedures. Rats were bled by orbital puncture with a glass capillary. Serum for each sample was collected from the pooled bleedings of five rats. The same rats were bled repeatedly throughout an experiment.
(iii) Cats. Before all treatments and bleedings, cats were inoculated intramuscularly with Vetalar (ketamine-hydrochloride) at a concentration of 11 mg/kg. This produced good restraint in about 3 min, and the animals appeared normal within 30 min post-treatment. U-25,166 was administrated orally by intubation through a no. 10 nelaton catheter purchased from Daval, Inc. (Providence, R.I.). A volume of 20 to 40 ml was administered, depending on the weight of the cat. Repeated serum samples were collected from each cat by bleeding from the jugular vein. ville, Md.). Monolayers were maintained in continuous culture using Eagle minimal essential medium supplemented with 10% fetal calf serum, 100 zg of streptomycin per ml, 100 U of penicillin per ml, and 2 mM glutamine (E-MEM-10 RESULTS The bioactivity of U-25,166 was'first detected in a mouse screen designed to detect endogenous interferon inducers. Multiple i.p. injections of U-254f66 protected mice from i.n. EMC infection. All mice survived when treated with five doses of 200 mg/kg, whereas minimum activity was,obtained at a dose of 50 mg/kg (Table  1) .
A substance inhibitory for vesicular stomatitis virus replication on L929' cells could be recovered'from the serum of mice treated with U-25,166. This virus inhibitory substance was characterized as an interferon based on the following criteria:' (i) it was not sedimented by centrifugation at 100,000 x g for 2 h; (ii) the inhibitor was stable at pH 2' for at least 4 days at 4 C; (iii) it did not inactivate vesicular stomatitis virus on direct contact, and the protective effect was not reversed by washing cells previously exposed to the inhibitor; (iv) the inhibitor found in mouse serum was effective as an antiviral on mouse cells but not on rabbit or chick cells; (v) the mouse serum-inhibitor 'was inactivated by trypsin; (vi) the inhibitor was not dialyzable; (vii) its in vitro action was suppressed by pretreatment of L929 cell cultures with 1 ,ug of actinomycin D per ml.
After discovery of the antiviral and interferon-inducing properties of U-25,166, some 75 pyrimidines, many of which differed in structure only slightly from U-25,166, were tested in EMC-infected mice. A summary of results ob- tained with 27 of the most closely related structural analogues, including all compounds found active, is shown in Table 2 . As indicated, removal of the 2-amino or its replacement with a methylamino group resulted in loss of antiviral activity. Replacing the 4-hydroxyl with either methyl or amino also gave inactive compounds. Activity was lost when the 6-methyl was removed or replaced with chloro or amino. The 6-ethyl analogue of U-25,166 was active, but the 6-propyl, -isopropyl, and -benzyl compounds were all inactive. If antiviral activity were to be retained, the 5-bromo in U-25,166 could be replaced by iodine but not by chlorine; in fact, iodo at the 5-position appeared to permit more diversity at position 6, with 5-iodo-6-chloro, 5-iodo-6-propyl, and 5-iodo-6-benzyl all showing antiviral activity. In these screening tests, none of the compounds was appreciably more active than U-25,166. This compound, therefore, was further evaluated to better define its interferon-inducing and antiviral potential. (Table 7) . Also shown in this table are approximate acute LD50 values for U-25,166 in noninfected 16-g mice. In another tolerance study, 12-to 13-g ICR mice were treated by various routes twice daily for 5 consecutive days with incremental levels of U-25,166 (Table 8 ). These data indicate that the drug is well tolerated in mice, both parenterally and p.o.
As noted in Table 3 , a single oral treatment of mice with U-25,166 produced high levels of circulating interferon through 12 h, lower levels at 24 h, and no detectable serum interferon at 48 h. An experiment was run to determine whether this pattern was consistent with duration of antiviral activity. At daily intervals, groups of 20 mice were treated orally with a single 1,000 mg/kg dose of U-25,166 in CMC. Control groups were treated with CMC only. All mice were challenged i.n. at zero time with (Table 11) .
DISCUSSION Interferon appears to possess many of the properties associated with the ideal antiviral agent, i.e., it is active against a broad spectrum of both ribonucleic acid and deoxyribonucleic acid viruses, it is apparently well tolerated in animals and man, it shows little antigenicity, and it is a natural substance produced physiologically, particularly as a result of viral infec- tion. There is good evidence that interferon represents one of the major host defense mechanisms for limiting the spread of viral infections.
Despite these desirable attributes of interferon as an antiviral agent, progress in the practical application of exogenous interferon has been slow. A major reason for this is the fact that interferon is essentially species specific, so that interferon for use in man must be produced in human cells. This requirement, and the difficulty of concentrating and purifying interferon, has resulted in a limited supply of human interferon for clinical studies. This limitation is likely to continue for the forseeable future.
Efforts have been directed, therefore, toward the discovery of agents which can be administered to the animal host, particularly to man, and will lead to the production of endogenous interferon. The rationale is that such agents could be given early in disease to shorten the course of clinical signs and symptoms or, if sufficiently well tolerated, could be given prophylactically to prevent viral infection. A variety of nonviral interferon inducers, which are effective in animals, have been discovered. Some of these are high-molecular-weight substances, such as pyran co-polymers and doublestranded polyribonucleotides. So far, experience with the polymers has indicated that they ANTIMICROB. AGErNTS CHEMOTHER.
are probably too toxic for widespread human use.
A limited number of relatively low-molecular-weight compounds have also been reported to induce interferon in animals. Among the first of these was tilorone hydrochloride, a fluorenone derivative (7, 8) . This compound is active p.o. and induces high levels of interferon in mice. It has been tested clinically but may have limited potential due to toxicity and lack of interferon induction in man (6) . Two other tricyclic ring compounds, quinacrine and acranil, which are used clinically as antiparasitic drugs, were also found to induce an interferonlike substance in mice (4). Siminoff et al. reported (10) that a substituted pyrazoloquinoline induced interferon and displayed antiviral activity in mice. Apparently the drug has not been evaluated clinically. A substituted propanediamine, CP-20,961, induced interferon and showed antiviral activity in mice, but only when given parenterally (5); there was no evidence of serum interferon in dogs, cats, rabbits, monkeys, or pigs after intramuscular administration of the compound (3). Nevertheless, CP-20,961, given intranasally to volunteers, induced measurable interferon (2, 3) in nasal secretions and showed significant protection against an experimental rhinovirus challenge (9) .
U-25,166, the substituted pyrimidine discussed in this report, represents another unique chemical structure which induces interferon in animals. Peak interferon titers in mouse sera occurred 6 to 12 h after treatment with U-25,166. By contrast, peak titers with the other low-molecular-weight inducers discussed above were reported to occur 18 to 24 h after drug treatment. This difference in response time may indicate a different mechanism of interferon induction or perhaps a different population of cells that is stimulated to produce interferon.
There is no apparent structural similarity among these several low-molecular-weight compounds now reported to be effective interferon inducers in mice. Despite this diversity of chemical inducers, there is apparently a rather strict limitation on the substitutions possible in a given compound if the property of interferon induction is to be retained (1). This is further illustrated in our experiments concerning the antiviral activity of various congeners of U-25,166. The structural specificity requirements, as illustrated in Table 2 , indicate that receptor sites on susceptible cells may be quite specific with respect to a given type of compound, even though a variety of parent compounds apparon November 3, 2017 by guest http://aac.asm.org/ Downloaded from ently are capable of stimulating interferon production. As the list of active types of compounds is enlarged, and the limitations on substitution with each compound type is defined, it may be possible to approach more rationally the synthesis of effective, well tolerated interferon inducers.
The potential practical utility of U-25,166 cannot be realistically evaluated as yet. An apparent disadvantage is the fact that the minimal effective dose in mice is relatively high. The compound does, however, appear to be well tolerated and induces good levels of interferon when administered p.o. as well as parenterally. Despite its discovery in a mouse screen, U-25,166 also induces interferon in a non-rodent, i.e., the cat. This observation is of possible practical importance because of the need for effective chemotherapeutic agents to treat a variety of feline viral diseases.
We are further evaluating U-25,166 as an interferon inducer and antiviral agent in other species. In addition, studies are under way to determine the cell types responsible for interferon production after treatment with U-25,166. These, as well as toxicology and pharmacology studies in animals, must be completed before assessing the clinical potential of U-25,166 in man.
